Abstracts tagged "depression"

Abstract Number: 1263 • ACR Convergence 2023
Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases
Luis Vega Sevilla¹, Miguel Villarreal-Alarcon², Diana Paola Flores-Gutierrez³, Maria Corral-Trujillo⁴, Ricardo Juarez⁴, Ivan Hernandez Galarza⁵, Jesus Alberto Cardenas-De la Garza⁶ and Dionicio A. Galarza-Delgado², ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵University Hospital, UANL, San Pedro Garza Garcia, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Depression is one of the most common psychiatric comorbidities in patients with rheumatic diseases. A study has shown that almost a third of patients…
Abstract Number: 2287 • ACR Convergence 2023
Mental Health of Lupus Erythematosus Patients Managed in an Academic Safety-Net Clinic
Reina Gonzalez, Eleni Pilitsi, Hanni Menn, Monica Crespo-Bosque, Michael York and Christina Lam, Boston University, Boston, MA
Background/Purpose: Lupus erythematosus (LE) is a complex autoimmune disease with heterogeneous manifestations ranging from life-threatening multi-organ inflammation in systemic lupus erythematosus (SLE) to limited skin…
Abstract Number: 1446 • ACR Convergence 2023
Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database
Iñigo Rúa-Figueroa¹, JULIA MARTINEZ BARRIO², Norman Jiménez³, Maria Galindo-Izquierdo⁴, Esther Uriarte Isacelaya⁵, Antonio Fernandez-Nebro⁶, Jaime Calvo- Alén⁷, SARA MANRIQUE⁸, Jose Rosas⁹, Rocío Caño-Alameda¹⁰, Javier Narvaez¹¹, Inmaculada Ros¹², Elena Aurrecoechea Aguinaga¹³, Vicente Torrente-Segarra¹⁴, Clara Sanguesa Gomez¹⁵, Mercedes Freire González¹⁶, Eva Tomero Muriel¹⁷, Loreto Horcada¹⁸, Clara Moriano Morales¹⁹, Mireia Moreno²⁰, Carlota Iñíguez²¹, Ricardo Blanco²², Ana Pérez Gómez²³, Jose Luis Andreu-Sánchez²⁴, Sandra Garrote Corral²⁵, Santiago Muñoz²⁶, Gema Bonilla²⁷, Nuria Lozano Rivas²⁸, Carlos Montilla-Morales²⁹, Oihane Ibarguengoitia-Barrena³⁰, Lorena Expósito³¹, Elia Valls-Pascual³², Angela Pecondon-Español³³, Sergio Machin³⁴, Eva Salgado-Pérez³⁵, Celia Erausquin³⁶, TAREK CARLOS SALMAN MONTE³⁷, Raúl Menor-Almagro³⁸, Alejandro Muñoz³⁹, Irene Altabas Gonzalez⁴⁰, Jorge Juan Fragio⁴¹ and Jose-Maria Pego-Reigosa⁴², ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ³IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁴Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁵Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁹Hospital Marina Baixa, Alicante, Spain, ¹⁰Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Rheumatology Department HUSLL, Palma de Mallorca, Spain, ¹³Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ¹⁴Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ¹⁵Severo Ochoa Hospital, Madrid, Spain, ¹⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁷Rheumatology, Hospital La Princesa, Madrid, Spain, ¹⁸Hospital de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Universitario de León, León, Spain, ²⁰Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²¹Hospital Lucus Augusti, Lugo, Spain, ²²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²³Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²⁴Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁵Hospital Ramón y Cajal, Madrid, Spain, ²⁶Hospital Infanta Sofia, Madrid, Spain, ²⁷Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁹Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ³⁰Galdakao-Usansolo University Hospital, Bilbao, Spain, ³¹Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³²Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, ³³Hospital Miguel Servet, Zaragoza, Spain, ³⁴CHUIMI, Las Palmas de Gran Canaria, Spain, ³⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ³⁶Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁷Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³⁸Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ³⁹Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ⁴⁰Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴¹Hospital General Universitario Valencia, Valencia, Spain, ⁴²Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: The prevalence of depression and associated factors in systemic lupus erythematosus (SLE) are not well known and there are no longitudinal studies addressing this…
Abstract Number: 2303 • ACR Convergence 2023
Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Jaime Vondenberg¹, Chao Zhang¹ and Emily Littlejohn², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…
Abstract Number: 1466 • ACR Convergence 2023
Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020
Shreena Kamlesh Gandhi¹, Abhiram Challa², Sandhya Shri Kanniyaram³, Arnav Kamat⁴, Tejasri Polana⁵ and Kaleb Michaud⁶, ¹Kansas University School of Medicine, Wichita, KS, ²KU School of Medicine, Wichita, KS, ³John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ⁴NYCH+H/Woodhull, New York, NY, ⁵Jawaharlal Nehru Medical College, Belgaum, Belgaum, India, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…
Abstract Number: 2322 • ACR Convergence 2023
Identifying SLE Patients with Depression Using a Zero-Inflated Hidden Markov Model and Predicting Factors Associated with Transition from a Non-depressed State to a Depressed State
Yasmin Nariman¹, Juan Pablo Diaz Martinez², Kathleen Bingham¹, Patti Katz³ and Zahi Touma⁴, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³University of California San Francisco, San Rafael, CA, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Depression is one of the most common neuropsychiatric disorders in patients with SLE. The Centre for Epidemiologic Studies Depression Scale (CES-D) has been used…
Abstract Number: 1578 • ACR Convergence 2023
Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis
Alejandra Espinosa-Orantes¹, David Vera-Bustamante², Jessica Roldan Ortega³, Maria Mejia-Avila⁴, Jose Raul Molina⁵, Evelyn Aranda Cano⁵, Adriana Miguel-Alvarez⁵, Ismael Valenzuela⁵, Viridiana Del Río-Guerrero⁶, Paloma Rodriguez⁵, Mauricio Mora-Ramirez⁵, Nilda Espinola-Zavaleta⁴, Luis H Silveira-torre⁶, Angélica Vargas Guerrero⁷ and Laura A Martínez-Martínez⁸, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ²BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA, Mexico City, Mexico, ³INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Mexico, ⁴Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Instituto Nacional de Cardiologia, Mexico City, Mexico, ⁶Instituto Nacional de Cardiología, Mexico City, Mexico, ⁷Instituto Nacional de Cardiología, Mexico City, Mexico, ⁸Universidad Nacional Autónoma de México - Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Takayasu arteritis (TAK) is a chronic, granulomatous large-vessel vasculitis. As TAK has a chronic course, higher frequency rates of anxiety and depression are reported…
Abstract Number: 2485 • ACR Convergence 2023
Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: In randomized placebo-controlled trials, including the phase 4 Belimumab Assessment of Safety in SLE study, belimumab use was associated with a higher incidence of…
Abstract Number: 1640 • ACR Convergence 2023
Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
Rebecca Haberman¹, Sydney Catron¹, Yu Veronica Sui¹, Sarah Moussavi¹, Soumya Reddy², Eileen Lydon³, Andrea Neimann¹, Alexis R Ogdie⁴, Mariana Lazar¹ and Jose Scher⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³New York University, New York, NY, ⁴University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in psoriatic disease (PsD) therapeutics, treatment response remains suboptimal. Even in patients with psoriatic arthritis (PSA) that achieve seemingly controlled inflammation,…
Abstract Number: 1828 • ACR Convergence 2023
Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission
Theodore Pincus¹, Rahel Hunter¹ and Nicholas Rodwell², ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Liverpool, Australia
Background/Purpose: DAS28 (disease activity score 28) and CDAI (clinical disease activity index) are prominent indices to assess patients with rheumatoid arthritis (RA) quantitatively, for which…
Abstract Number: 1837 • ACR Convergence 2023
Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia
Irakli Tskhakaia¹, Pushti Khandwala¹ and Irene Tan², ¹Albert Einstein Medical Center Philadelphia, Philadelphia, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Suicide and depression represent a high burden of morbidity and mortality worldwide. It is well known that fibromyalgia (FM) is associated with mood and…
Abstract Number: 0121 • ACR Convergence 2023
High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Jeong Yee¹, Candace Feldman¹, Emily G. Oakes¹, Elizabeth Karlson¹, Jack Ellrodt¹, Laura Kubzansky², Karestan Koenen² and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are complex autoimmune diseases associated with pain and decreased quality of life. Mental health conditions related…
Abstract Number: 1838 • ACR Convergence 2023
The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility
Alizée Perrein¹, Fabien Pontille¹, Paul Decker², david Attali³, Thomas Moulinet⁴ and Roland Jaussaud⁵, ¹Département de Médecine interne et immunologie clinique, Université de Lorraine / CHRU de Nancy, Vandoeuvre-les-Nancy, France, ²Nancy hospital, France, Nancy, France, ³Université Paris Cité, Laboratoire Psychopathologie et Processus de Santé, Boulogne-Billancourt, France, ⁴Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, ⁵Département de Médecine interne et immunologie clinique, Université de Lorraine / CHRU de Nancy, Vandoeuvre Les Nancy, France
Background/Purpose: Hypermobility spectrum disorders (HSD) and hypermobile Ehlers Danlos syndrome (hEDS) are among the conditions associated with generalized joint hypermobility (GJH). Alongside myofascial and skeletal…
Abstract Number: 0150 • ACR Convergence 2023
Self-reported Levels of Physical Activity and the Association to Pain, Fatigue, Anxiety and Depression Among Patients with Idiopathic Inflammatory Myopathies
Kristofer Andreasson¹, Fabricio Espinosa-Ortega², Heléne Sandlund³ and Helene Alexanderson⁴, ¹Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with inflammatory diseases such as rheumatoid arthritis exhibit reduced levels of physical activity (PA) compared to the normative population and suffer from anxiety…
Abstract Number: 1857 • ACR Convergence 2023
More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen)
Juan Schmukler and Theodore Pincus, Rush University Medical Center, Chicago, IL
Background/Purpose: Treat to target in rheumatoid arthritis (RA) suggests escalation of therapy in patients whose scores are high or moderate on a disease activity index…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].